Xinyang Medical College Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2014
NCT02025036
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

The First Affiliated Hospital of Xinyang Medical College

Active Ingredients

Drugs in Phase 3 Trials (2)

capecitabine (xeloda) (1 trial)

human choriogonadotropin alfa (hCG) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2